The consortium, launched at the end of March, now has six organizations pitching in on the collective effort to share data and analysis. The companies will work together to integrate data from current and future clinical research, with the intention of accelerating discovery of a cure by up to 50%.
Kenneth Massey, chief life sciences officer for Saama Technologies, said finding viable treatments as fast is important to protect the health of people everywhere.
“The new EndPandemic National Data Consortium partners are to be applauded for the speed with which they answered the call to protect and ensure public health,” he said. "The integrated database developed by the Consortium will be a comprehensive, collective platform that will inform and accelerate medical experts’ abilities to arrive at actionable decisions in relation to COVID-19 clinical research.”
Founded by Saama, the EndPandemic National Data Consortium’s value proposition, strategic direction, charter and business plan development are being headed by life-science data specialists Zaylan Associates and its partner Chrysalis Biomedical Advisors.
To date, six organizations have signed up to contribute to the efforts of the consortium. Their work is geared toward facilitation of clinical trial data sharing among and across sectors, ultimately creating a a continually updated data repository for researchers around the globe to us.
Healthcare communications firm Andaman7 has built a COVID-19 patient symptom survey with electronic health record (EHR) and device integration. The tool is designed to help patients grasp their personal risk of contracting COVID-19 through symptom tracking and information.
Available in 22 languages, the platform is HIPAA, GDPR, and 21CFRPart11 compliant. The technology delivers information and guidance to patients, providing access to more 10,000 clinics and hospital EMRs in the US.
Caprion Biosciences Inc.
Caprion Biosciences Inc. (a provider of specialized immunology, genomics and proteomics laboratory services) offers advanced immune monitoring services. These include phenotypic and functional analyses of innate and adaptive immune responses in patients treated with innovative immunomodulating drugs and vaccines.
In addition to its expertise in the development and clinical deployment of laboratory assays and tests, the company’s data integration and biostatistical analyses of large data sets will allow partners to decipher the optimal treatment combinations and vaccine strategies, via a biomarker-driven approach.
Clinerion’s Patient Network Explorer is a global patient data network platform, offering near-real-time access to the EHR-based data of more than 27 million patients. The platform enables flexible queries of demographic data, diagnoses, medications and procedures, and laboratory results, and includes event-based and temporal constraint capabilities.
The firm supports research and real-world evidence (RWE) queries for COVID-19 cases, epidemiology, and health economics and outcomes research. It can track and analyze complex combinations of patient data, longitudinally, to understand patient treatment diagnostics, treatment modalities, co-morbidities and developing cohort and outcome models by country and health care institution.
INDX.AI is a data analytics software company providing solutions intended to accelerate translational research in precision medicine-based clinical trials. The technology employs bio markers and AI-enabled multi-omics data analytics.
Additionally, the company’s iCore Platform is being adapted to accelerate translational research with in silico biomarker discovery for COVID-19 clinical trials.
The company’s AI-powered Life Science Analytics Cloud (LSAC) technology platform will enable researchers to visualize, analyze, and interrogate data across all available programs. The platform integrates, curates, and animates clinical trial data, delivering actionable insights for rapid decision making.
Further, the company has leveraged the platform’s deep learning capabilities to enable queries of the COVID-19 Open Research Dataset (CORD-19), a publicly available database that contains more than 45,000 scholarly articles giving the medical community access to the most up-to-date research.
Zaylan Associates and Chrysalis Biomed Advisors
The two companies will focus developing the consortium’s value proposition, strategic direction, charter and business plan.
The consortium is open to additional clinical research organizations, biopharmaceutical companies, data analysis specialists and government agencies. Additional information is available on the consortium website, EndPandemic.org.